Zorlu Ferruh, Zorlu Rauf, Divrik Rauf Taner, Eser Sultan, Yorukoglu Kutsal
Department of Urology, Ministry of Health Tepecik Research and Training Hospital, Izmir, Turkey E-mail :
Asian Pac J Cancer Prev. 2014;15(21):9125-30. doi: 10.7314/apjcp.2014.15.21.9125.
This study aimed to determine the incidence of prostate cancer in Turkey in a population-based sample, and to determine clinical and pathological characteristics of the cases.
All newly diagnosed prostate cancer patients were included in this national, multi-centered, prospective and non- interventional epidemiological registry study conducted in 12 cities representing the 12 regions of Turkey from July 2008 to June 2009. The population-based sample comprised 4,150 patients with a recent prostate cancer diagnosis.
Age-adjusted prostate cancer incidence rate was 35 cases per 100,000 in Turkey. At the time of diagnosis, median age was 68, median PSA level was 10.0 ng/mL. Digital rectal examination was abnormal in 36.2% of 3,218 tested cases. Most patients had urologic complaints. The main diagnostic method was transrectal ultrasound guided biopsy (87.8%). Gleason score was ≤6 in 49.1%, 7 in 27.8% and >7 in 20.6% of the cases. There was a statistically significant positive correlation between serum PSA level and Gleason score (p=0.000). The majority of patients (54.4%) had clinical stage T1c.
This is the first population-based national data of incidence with the histopathological characteristics of prostate cancer in Turkey. Prostate cancer remains an important public health concern in Turkey with continual increase in the incidence and significant burden on healthcare resources.
本研究旨在确定以人群为基础的土耳其样本中前列腺癌的发病率，并确定病例的临床和病理特征。
所有新诊断的前列腺癌患者均纳入了这项全国性、多中心、前瞻性且非干预性的流行病学登记研究，该研究于2008年7月至2009年6月在代表土耳其12个地区的12个城市开展。以人群为基础的样本包括4150例近期诊断为前列腺癌的患者。
土耳其年龄调整后的前列腺癌发病率为每10万人中有35例。诊断时，中位年龄为68岁，中位前列腺特异抗原（PSA）水平为10.0 ng/mL。在3218例接受检测的病例中，36.2%的直肠指检结果异常。大多数患者有泌尿系统症状。主要诊断方法是经直肠超声引导下活检（87.8%）。病例中Gleason评分≤6的占49.1%，评分为7的占27.8%，评分>7的占20.6%。血清PSA水平与Gleason评分之间存在统计学上显著的正相关（p = 0.000）。大多数患者（54.4%）临床分期为T1c。
这是土耳其首个基于人群的前列腺癌发病率及组织病理学特征的全国性数据。前列腺癌在土耳其仍然是一个重要的公共卫生问题，发病率持续上升，给医疗资源带来巨大负担。
